Morin Sarah, Boroli Filippo, Vandenberghe-Durr Sophie, Allali Daniele, Masouridi-Levrat Stavroula, Chalandon Yves, Simonetta Federico
Department of Oncology Division of Hematology Geneva University Hospitals Geneva Switzerland.
Department of Medicine Faculty of Medicine Translational Research Center for Oncohematology University of Geneva Geneva Switzerland.
EJHaem. 2024 Apr 19;5(3):603-606. doi: 10.1002/jha2.874. eCollection 2024 Jun.
Anaphylactic reactions at the time of chimeric antigen receptor T (CAR-T) cell infusion are adverse events that have not been reported in pivotal clinical trials or in real-world series. We report the case of patient with severe anaphylaxis with cardiac arrest after tisagenlecleucel injection for Diffuse Large B cell Lymphoma, who recovered after resuscitation and intensive care treatment; we also conducted a Food and Drug Administration Adverse Event Reporting System database analysis and found several cases of severe anaphlyaxis after CAR-T cell injection. Although not reported in pivotal CAR-T cell studies, anaphylaxis can occur after CAR-T cell injection, highlighting the need to include anaphylaxis as a possible side effect in future studies.
嵌合抗原受体T(CAR-T)细胞输注时的过敏反应是在关键临床试验或真实世界系列报道中均未出现过的不良事件。我们报告了1例弥漫性大B细胞淋巴瘤患者在注射替沙格韦单抗后发生严重过敏反应并伴有心脏骤停的病例,该患者经复苏和重症监护治疗后康复;我们还对美国食品药品监督管理局不良事件报告系统数据库进行了分析,发现了几例CAR-T细胞注射后发生严重过敏反应的病例。尽管在关键的CAR-T细胞研究中未报告,但CAR-T细胞注射后可能发生过敏反应,这凸显了在未来研究中将过敏反应作为可能的副作用纳入考量的必要性。